June 01, 2022

The American Medical Association (AMA) has announced an update to the Current Procedural Terminology (CPT)^® set of codes, to now include the Moderna COVID-19 vaccine for children aged 6 months to 5 years.

CPT codes clinically distinguish each coronavirus vaccine to enable data-driven tracking, reporting and analysis that has helped streamline the public health response to the pandemic.

The interim CPT codes will go into effect if Moderna’s COVID-19 pediatric vaccine candidate receives emergency use authorization from the U.S. Food and Drug Administration (FDA). WADA releases CPT code update to ensure smooth digital transition in US healthcare system ahead of potential FDA clearance.

AMA also offers a vaccine code finder to help identify the appropriate CPT code combination for the type and dose of COVID-19 vaccine provided to each patient. This process facilitates accurate coding and reporting of COVID-19 vaccines and immunization services.

The new product code and long descriptor for the pediatric vaccine are:

• 91311: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, strength 25 mcg/0.25 mL, for intramuscular use

The new administration codes and long descriptors for the pediatric vaccine are:

• 0111A: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) intramuscular injection immunization administration (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, no preservative, 25 mcg/0.25 mL dose; first dose
• 0112A: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) intramuscular injection immunization administration (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, no preservative, 25 mcg/0.25 mL dose; second dose

For more information, please visit the WADA website.

Additional Resources:

Come back